Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation

Cancer Journal

Volumn 17, Issue 3, 2011, Pages 159-165

  Brizel, David M ^a  

^a University Cancer Institute   (United States)

Author keywords

diffusion weighted MRI; dynamic contrast enhanced MRI; functional imaging; Head and neck cancer; PET scanning; positron emission tomography

Indexed keywords

DIFFUSION WEIGHTED IMAGING; HEAD AND NECK CANCER; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 79958819674     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31821e8a09     Document Type: Review

References (77)

1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
2. Graff BA, Benjaminsen IC, Brurberg KG, et al. Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging. J Magn Reson Imaging. 2005;21:272-281. (Pubitemid 40280122)
3. Rijpkema M, Kaanders JH, Joosten FB, et al. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging. 2001;14:457-463. (Pubitemid 32906564)
4. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232.
5. Cooper RA, Carrington BM, Loncaster JA, et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol. 2000;57:53-59.
6. George ML, Dzik-Jurasz AS, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001;88:1628-1636. (Pubitemid 33124241)
7. Hawighorst H, Knapstein PG, Knopp MV, et al. [Angiogenesis of cervix carcinoma. Contrast enhanced dynamic MRI, histologic quantification of capillary density and lymphatic system infiltration]. Radiologe. 1998;38:50-57.
8. Stomper PC, Winston JS, Herman S, et al. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat. 1997;45:39-46. (Pubitemid 27338530)
9. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777. (Pubitemid 46622044)
10. Ohno Y, Nogami M, Higashino T, et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging. 2005;21:775-783. (Pubitemid 40770870)
11. Loncaster JA, Carrington BM, Sykes JR, et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002;54:759-767.
12. Yamashita Y, Baba T, Baba Y, et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology. 2000;216:803-809. (Pubitemid 30660858)
13. Baba Y, Yamashita Y, Onomichi M. Dynamic MR imaging and radiotherapy. Magn Reson Med Sci. 2002;1:32-37.
14. Hoskin PJ, Saunders MI, Goodchild K, et al. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol. 1999;72:1093-1098.
15. Tomura N, Omachi K, Sakuma I, et al. Dynamic contrast-enhanced magnetic resonance imaging in radiotherapeutic efficacy in the head and neck tumors. Am J Otolaryngol. 2005;26:163-167. (Pubitemid 41583242)
16. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed. 2002;15:132-142. (Pubitemid 34213403)
17. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28.
18. Morgan B, Utting JF, Higginson A, et al. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. British journal of cancer. 2006;94:1420-1427. (Pubitemid 43772276)
19. Kim S, Loevner LA, Quon H, et al. Prediction of response to chemo-radiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2009;31:262-268.
20. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008;14:6580-6589.
21. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007;25:4104-4109. (Pubitemid 47495868)
22. Wang J, Takashima S, Takayama F, et al. Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology. 2001;220:621-630. (Pubitemid 32799967)
23. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging. 2006;6:135-143.
24. Nagata S, Nishimura H, Uchida M, et al. Diffusion-weighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis. Radiat Med. 2008;26:287-295.
25. Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol. 2010;20:1703-1714.
26. Hamstra DA, Lee KC, Moffat BA, et al. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol. 2008;1:187-194.
27. Vandecaveye V, de Keyzer F, Vander Poorten V, et al. Evaluation of the larynx for tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in four cases. Br J Radiol. 2006;79:681-687. (Pubitemid 44283158)
28. Harry VN, Semple SI, Gilbert FJ, et al. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol. 2008;111:213-220.
29. Kim H, Morgan DE, Buchsbaum DJ, et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res. 2008;68:8369-8376.
30. Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging. 2008;27:1109-1113. (Pubitemid 351614624)
31. Dirix P, De Keyzer F, Vandecaveye V, et al. Diffusion-weighted magnetic resonance imaging to evaluate major salivary gland function before and after radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:1365-1371.
32. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387-3394.
33. Galban CJ, Mukherji SK, Chenevert TL, et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol. 2009;2:184-190.
34. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemo-radiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res. 2009;15:986-994.
35. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. [Published online ahead of print January 18, 2011.] Head Neck.
36. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
37. 18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50:1028-1035.
38. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
39. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171-1182. (Pubitemid 32184623)
40. Brizel DM, Rosner GL, Prosnitz LR, et al. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys. 1995;32:1121-1125.
41. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996;56:5522-5528. (Pubitemid 27011389)
42. Lanzen J, Braun RD, Klitzman B, et al. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res. 2006;66:2219-2223.
43. Pigott KH, Hill SA, Chaplin DJ, et al. Microregional fluctuations in perfusion within human tumours detected using laser Doppler flow-metry. Radiother Oncol. 1996;40:45-50. (Pubitemid 26246264)
44. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70: 1219-1228.
45. 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med. 2009;50:1646-1654.
46. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423-1426. (Pubitemid 351417756)
47. Faria SL, Menard S, Devic S, et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys. 2008;70:1035-1038. (Pubitemid 351296113)
48. Ha PK, Hdeib A, Goldenberg D, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:12-16. (Pubitemid 43127956)
49. Ung YC, Maziak DE, Vanderveen JA, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99:1753-1767. (Pubitemid 351767209)
50. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583-1593. (Pubitemid 47476915)
51. Di Fabio F, Pinto C, Rojas Llimpe FL, et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer. 2007;10:221-227. (Pubitemid 350308171)
52. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
53. Nishiyama Y, Yamamoto Y, Kanenishi K, et al. Monitoring the neo-adjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging. 2008;35:287-295.
54. Port JL, Lee PC, Korst RJ, et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg. 2007;84:393-400; discussion.
55. 18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478.
56. Greven KW, Mattern D, West M, et al. Prospective study of serial PET/CT imaging for patients with squamous cell cancer of the head and neck and the possibility of adaptive planning. Int J Radiat Oncol Biol Phys. 2009;75:S394.
57. Higgins KA, Hoang JK, Roach MC, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUV(mean) has superior prognostic value. [Published online ahead of print February 1, 2011.] Int J Radiat Oncol Biol Phys.
58. 18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-5868.
59. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335-1341.
60. Mukherji SK, Wolf GT. Evaluation of head and neck squamous cell carcinoma after treatment. AJNR Am J Neuroradiol. 2003;24:1743-1746. (Pubitemid 37280517)
61. Terhaard CH, Bongers V, van Rijk PP, et al. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck. 2001;23:933-941. (Pubitemid 32977535)
62. 18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199-4208.
63. 18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer - a long-term outcome report. Int J Radiat Oncol Biol Phys. 2008.
64. Wong SJ, Harari PM, Garden AS, et al. Longitudinal oncology registry of head and neck carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer. 2010.
65. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg. 2007;133:435-440. (Pubitemid 46799778)
66. 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532-540.
67. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope. 2007;117:2129-2134. (Pubitemid 351339585)
68. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981-991. (Pubitemid 44633504)
69. Blanco AI, Chao KS, El Naqa I, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1055-1069. (Pubitemid 40884418)
70. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695-704. (Pubitemid 32515326)
71. Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg. 2003;27:832-837. (Pubitemid 37022398)
72. Eisbruch A, Dawson LA, Kim HM, et al. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life. Acta Otorhinolaryngol Belg. 1999;53:271-275.
73. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873-4879. (Pubitemid 350220416)
74. Juan CJ, Chen CY, Jen YM, et al. Perfusion characteristics of late radiation injury of parotid glands: quantitative evaluation with dynamic contrast-enhanced MRI. Eur Radiol. 2009;19:94-98.
75. 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020-1027.
76. Roach MC, Turkington TG, Higgins KA, et al. FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. [Published online ahead of print October 30, 2010.] Int J Radiat Oncol Biol Phys.
77. 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys. 2010;77:1403-1410.